Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China
These findings indicate that PP1M significantly alleviates psychotic symptoms in patients with schizophrenia, accelerates social function recovery, and improves quality of life and patient satisfaction. Furthermore, PP1M demonstrates improved tolerability, fewer adverse reactions, and no new drug-related safety concerns.
Authors
- Rong-cheng Su
- Bo Zhou (ORCID: https://orcid.org/0000-0001-5811-0403)
- Jing Li (ORCID: https://orcid.org/0000-0002-5102-4315)
- Li Li (ORCID: https://orcid.org/0000-0001-5575-0894)
- Hui Li (ORCID: https://orcid.org/0000-0002-7516-7126)
- Lihong Huang (ORCID: https://orcid.org/0000-0002-6745-546X)
- Ruiqing Guo
- Ling Gou (ORCID: https://orcid.org/0000-0002-4739-9798)
Institutions
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- BMC Psychiatry
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1186/s12888-025-06646-1
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94